Original language | English (US) |
---|---|
Pages (from-to) | 2432-2433 |
Number of pages | 2 |
Journal | JAMA |
Volume | 326 |
Issue number | 23 |
DOIs | |
State | Published - Dec 21 2021 |
ASJC Scopus subject areas
- General Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: JAMA, Vol. 326, No. 23, 21.12.2021, p. 2432-2433.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Healing and Health Equity for Asian American, Native Hawaiian, and Pacific Islander Populations
AU - Taparra, Kekoa
AU - Harding, Michael
AU - Deville, Curtiland
N1 - Funding Information: Author Affiliations: Franklin Pierce School of Law, University of New Hampshire, Concord (Marks); Harvard Law School, Boston, Massachusetts (Marks). Corresponding Author: Mason Marks, MD, JD, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, 23 Everett St, Cambridge, MA 02138 ([email protected]). Conflict of Interest Disclosures: Dr Marks reported receiving a salary from the Project on Psychedelics Law and Regulation at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, which is funded by a grant from the Saisei Foundation, a nonprofit organization based in Austin, Texas; serving in a volunteer position as a governor-appointed member of the Oregon Psilocybin Advisory Board; and advising clients as a licensed attorney on state and federal controlled substance regulation. Funding Information: Conflict of Interest Disclosures: Dr Koh reported receiving funding from the Robert Wood Johnson Foundation during the conduct of the study. Mr Caballero reported being employed by the Association of Asian Pacific Community Health Organizations. No other disclosures were reported. Funding Information: Funding/Support: Dr Delnevo, Ms Miller Lo, and Drs Giovenco, Hrywna, and Strasser were supported by Tobacco Centers of Regulatory Science award U54CA229973 from the National Cancer Institute (NCI) and the FDA. Dr Giovenco was also supported by the Office of the Director at the National Institutes of Health (DP5OD023064). Dr Cornacchione Ross was supported by the NCI and FDA (R01CA260460).
PY - 2021/12/21
Y1 - 2021/12/21
UR - http://www.scopus.com/inward/record.url?scp=85122087847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122087847&partnerID=8YFLogxK
U2 - 10.1001/jama.2021.19243
DO - 10.1001/jama.2021.19243
M3 - Letter
C2 - 34932087
AN - SCOPUS:85122087847
SN - 0098-7484
VL - 326
SP - 2432
EP - 2433
JO - JAMA
JF - JAMA
IS - 23
ER -